An FDA-Approved Tenofovir Alafenamide-Based Antiretroviral Therapy Reduces Biological Age in Healthy Adults: First Human Proof-of-Concept for Retrotransposon-Targeted Gerotherapeutics
Preprint
Abstract
Nucleos(t)ide reverse transcriptase inhibitors (NRTIs) used for HIV treatment and pre-exposure prophylaxis have been proposed as gerotherapeutics based on their capacity to suppress age-associated retrotransposon activity. However, evidence in humans is currently lacking. Here we evaluated DNA methylation–based measures of biological aging in healthy people without HIV (aged 18–50) using samples from two separate randomized, directly observed dosing pharmacokinetic studies of FDA-approved NRTI regimens containing emtricitabine–tenofovir-alafenamide (FTC/TAF;200 mg/25 mg) or FTC-tenofovir-disoproxil fumarate (FTC/TDF; 200 mg/300 mg) for 12 weeks. In the FTC/TAF study (N=36), epigenetic aging measures based on DNA methylation (DNAm) profiling decreased over follow-up, including DunedinPACE (−0.061, p=0.019) and PhenoAge (−6.33, p=0.008), with concordant reductions (p<0.05) across additional systems-specific epigenetic clocks including those estimating brain aging. DNAm–based proxies of inflammatory biomarkers also declined, with significant reductions in epigenetic IL-6 (−0.058, p=0.029) and a trend toward reduced C-reactive protein (−0.231, p=0.059). In contrast, the FTC/TDF study (N=43) showed no significant changes across epigenetic clocks and proxies. These findings are consistent with TAF’s more favorable cellular pharmacology compared with TDF and support gerotherapeutic effects of FTC/TAF. Prospective placebo-controlled studies are warranted that integrate clinical pharmacology, direct transposable element readouts, and prespecified geroscience and DNA methylation–based aging endpoints.Keywords
This publication has 50 references indexed in Scilit:
- Nucleoside reverse transcriptase inhibitors as a therapeutic opportunity to counteract inflammaging and age-related diseases: New evidence from epidemiological dataAgeing Research Reviews, 2025
- Repurposing nucleoside reverse transcriptase inhibitors (NRTIs) to slow agingAgeing Research Reviews, 2023
- Resurrection of endogenous retroviruses during aging reinforces senescenceCell, 2023
- Hallmarks of aging: An expanding universeCell, 2023
- LINE1 Derepression in Aged Wild-Type and SIRT6-Deficient Mice Drives InflammationCell Metabolism, 2019
- Covalent inhibition of carboxylesterase-2 by sofosbuvir and its effect on the hydrolytic activation of tenofovir disoproxilJournal of Hepatology, 2017
- Genome-wide Methylation Profiles Reveal Quantitative Views of Human Aging RatesMolecular Cell, 2013
- A LINE-1 component to human aging: Do LINE elements exact a longevity cost for evolutionary advantage?Mechanisms of Ageing and Development, 2010
- L1 mobile element expression causes multiple types of toxicityGene, 2008
- Are transposons a cause of ageing?Mutation Research/DNAging, 1990